About Biotie
Biotie is a company based in Turku (Finland) founded in 1998 was acquired by Acorda in January 2016. Biotie has raised $149.81 million across 4 funding rounds from investors including Acorda and The Baupost Group. The company has 27 employees as of December 31, 2022. Biotie has completed 2 acquisitions, including Elbion and Synosia Therapeutics. Biotie operates in a competitive market with competitors including Indivior, Ethypharm, Braeburn, Amygdala Neurosciences and Cessation Therapeutics, among others.
- Headquarter Turku, Finland
- Employees 27 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biotie
Biotie has successfully raised a total of $149.81M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biotie
Biotie has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Acorda and The Baupost Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Conducts long-term value-oriented investments for families, foundations, and institutions.
|
Locked | Locked | Locked | |
|
Engaged in the development and commercialization of therapies that improve neurological function.
|
Locked | Locked | Locked |
Investor details for Biotie
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biotie
Biotie has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Elbion and Synosia Therapeutics.
Investment portfolio details for Biotie
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for CNS disorders including Parkinson's are developed.
|
Locked | Locked | 2005 | Locked | |
|
Small molecules for CNS and inflammatory diseases were discovered.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for Biotie
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biotie
Detailed financials for Biotie
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biotie Comparisons
Peer comparison for Biotie
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biotie
Biotie operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, Braeburn, Amygdala Neurosciences and Cessation Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Long-acting therapies for opioid addiction and chronic pain are developed.
|
|
| Locked | Locked | Locked |
Therapies for substance use disorders are developed by Amygdala Neurosciences.
|
|
| Locked | Locked | Locked |
Developer of immunotherapy based vaccines to manage addictions
|
|
| Locked | Locked | Locked |
Developer of small molecule drugs targeting CB1 receptor for CNS diseases
|
Detailed competitors of Biotie
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biotie
Complete news archive for Biotie
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotie
Biotie was founded in 1998 and raised its 1st funding round 15 years after it was founded.
Biotie is headquartered in Turku, Finland. It is registered at Turku, Varsinais-suomi, Finland.
Jari Saarinen is the current CEO of Biotie.
Biotie is a funded company, having raised a total of $149.81M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Biotie is 27.
Biotie was founded in 1998 in Turku, Finland, as a biotech firm specializing in drug development for central nervous system disorders. Operations center on advancing treatments for neurodegenerative and psychiatric conditions, including Selincro for alcohol dependency, which is marketed in Europe by H. Lundbeck AS, and Tozadenant, now entering Phase 3 trials for Parkinsons disease. The company operates in the commercial stage of biotechnology.
Biotie's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
Biotie has made 2 acquisitions, including Elbion, and Synosia Therapeutics.
Biotie has 2 investors. Key investors include Acorda, and The Baupost Group.